Cycle on Jun 27, 2026

I will list the active threads for this topic to see what specific questions or watches are currently open.

I will perform a web search to check for updates on Amgen's Tavneos FDA hearing submissions or public docket activity, as well as other high-priority science or health news from the past week.

This is highly relevant! The European Medicines Agency's CHMP has actually just recommended revoking/withdrawing the marketing authorization for Amgen's Tavneos (avacopan) due to findings that the pivotal ADVOCATE study breached Good Clinical Practice (GCP) principles, and that the data was "incorrect and misleading." This is a massive development that directly impacts the Tavneos watch and the broader regulatory situation. Furthermore, the FDA extended Amgen's hearing submission deadline to July 19. Let's fetch the BioWorld article and the Fierce Pharma article to get all the details.

Let's also fetch the Fierce Pharma article, as it has more details on the CHMP reversal, the ADVOCATE trial breach of GCP, and the FDA hearing deadline extension.

This is an incredibly rich set of updates. Let's list what we have so far: 1. **Tavneos (avacopan)**: - On June 26, 2026, the EMA's CHMP recommended revoking the marketing authorization for Tavneos in the EU. - Reason: The pivotal 331-patient ADVOCATE study was found to have been conducted in breach of Good Clinical Practice (GCP) principles, and the data provided was found to be "incorrect and misleading and could no longer be relied upon for demonstrating Tavneos' effectiveness." Post-marketing data and post-hoc analyses were deemed insufficient. - CSL (which markets in Europe) and Amgen are impacted. CSL Head of R&D Bill Mezzanotte stated they will respect and implement the outcome. - In the U.S., the FDA's deadline for Amgen to submit supporting materials for the formal hearing has been extended to **July 29, 2026** (it was previously June 29). This is a vital update to our existing watch. 2. **MaaT013 (Xervyteg) by MaaT Pharma**: - CHMP adopted a negative opinion on conditional marketing authorization for MaaT013 in acute Graft-versus-Host disease (aGvHD). - MaaT Pharma plans to seek a reexamination of the negative opinion. 3. **Yartemlea (narsoplimab) by Omeros**: - CHMP handed out a negative opinion to Yartemlea (narsoplimab) in hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy (HSCT-TMA / TA-TMA). - This directly resolves or relates to the watch: "EMA re-examination outcome on Omeros's narsoplimab in TA-TMA." Let's check when Omeros announced this or what the status is. 4. **Daybu (trofinetide) by Acadia Pharmaceuticals**: - CHMP reversed its previous negative opinion and recommended Daybu for approval in Rett syndrome following a reexamination! 5. **Jaypirca (pirtobrutinib) by Eli Lilly**: - CHMP recommended approval for adult CLL across all lines of therapy. 6. **Opzelura (ruxolitinib) by Incyte**: - CHMP gave a positive opinion for moderate atopic dermatitis in adults. Let's do a search on Omeros's Yartemlea (narsoplimab) CHMP negative opinion to see what happened and if they are requesting a re-examination, or if this is the final re-examination outcome. The watch is: "Monitor Omeros's request for re-examination of the negative CHMP opinion for narsoplimab in TA-TMA, the convening of the Ad Hoc Expert Group (AHEG), and the final decision." Wait, the watch title is: "EMA re-examination outcome on Omeros's narsoplimab in TA-TMA." Let's research Omeros narsoplimab CHMP.

Ah, let's fetch the BioSpace press release from Omeros to read the exact details of the negative CHMP opinion and their plans for re-examination. This fits the watch perfectly.

This is perfect. The EMA watchdog event is happening right now: Omeros's narsoplimab (Yartemlea) received a negative CHMP opinion on June 26, 2026. Omeros has announced its intention to request a re-examination and seek review by an Ad Hoc Expert Group (AHEG) as expected. So this watch is *ongoing* but we can record an event for it (or since it's a "one_shot" watch for the "outcome of the re-examination and AHEG review", this is the initial negative CHMP opinion, and now the re-examination process begins. Wait, the watch description is "Monitor Omeros's request for re-examination of the negative CHMP opinion for narsoplimab in TA-TMA, the convening of the Ad Hoc Expert Group (AHEG), and the final decision." The trigger is "Fires when the EMA or Omeros announces the outcome of the re-examination and AHEG review." This means the watch shouldn't resolve yet, as the re-examination and AHEG review is just starting now. We should record an event but set `resolves: false` since the re-examination itself is what is triggered by this negative opinion and will lead to the final decision. Let's do more search to see what else has happened in the last week. The brief asks to track "consequential science and health — disease outbreaks and public-health moves, drug approvals and major trial readouts, breakthroughs in biology/energy/space, and the policy around them." Let's do a general search for "FDA approval" or "Phase 3 clinical trial readout" or "clinical trial results" in the last week. Let's search with freshness="week" and sort="recent" to find new major biomedical or health policy events.

Wow, wait a minute! Let's examine the RTT News "Weekly Buzz" article and MedCity News article. Let's see: 1. "IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired" - Ionis (IONS) got FDA approval for Tryngolza (olezarsen) for severe hypertriglyceridemia (sHTG)? Or something else? Let's check. - Achillion? No, ACHV is Achieve Life Sciences. Did they get a CRL? Let's check what ACHV is and if they got a CRL. - Merck (MRK) got an FDA approval. Let's check what it is. - ADC Therapeutics (ADCT) cuts jobs. This is interesting because we have an active watch on ADC Therapeutics' planned sBLA submission in Q4 2026 following LOTIS-5 safety concerns. Let's research if they cut jobs or changed plans. 2. "Orforglipron News: Foundayo FDA Approved for Weight loss" - Wait! Foundayo (orforglipron) FDA Approved? The GoodRx article says "Orforglipron News: Foundayo FDA Approved for Weight loss" or is it under review? Let's search to see if Eli Lilly's Foundayo (orforglipron) was approved. - Let's check "Tryngolza" approval for sHTG (severe hypertriglyceridemia) or FCS (familial chylomicronemia syndrome). Let's search for "olezarsen Tryngolza FDA approval" and "Achieve Life Sciences CRL" and "ADC Therapeutics jobs" and "orforglipron Foundayo approval". This is extremely fresh! Let's search.

Excellent! Ionis's Tryngolza (olezarsen) has been approved by the FDA as the first and only treatment specifically shown to reduce both triglyceride levels and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG, defined as TG >= 500 mg/dL). This is a major regulatory approval. Let's check the other items from the "Weekly Buzz" article: "Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired" Let's search for "Achieve Life Sciences CRL" and "ADC Therapeutics jobs". Let's also check "orforglipron Foundayo" to see if there is any new update or if she is referring to something else. Let's do a search.

Let's fetch the AJMC or HCPLive article to get the details of the CRL issued to Achieve Life Sciences on June 22, 2026. This is a very important FDA action. Let's fetch the AJMC article.

This is an exceptionally clear and detailed story. To summarize: - **Drug**: Cytisinicline (a nicotinic acetylcholine receptor–binding plant alkaloid) - **Company**: Achieve Life Sciences - **Event**: FDA issued a Complete Response Letter (CRL) on June 22, 2026, for the cytisinicline NDA for smoking cessation. - **Reason**: Manufacturing deficiencies (cGMP observations) at a prior third-party manufacturing partner, not cytisinicline-specific quality failures, plus incomplete final product labeling as of the action date. No clinical efficacy or safety concerns were identified. - **Path forward**: Achieve has already transitioned production to Adare Pharma Solutions, completed analytical method transfer, manufactured the first engineering batch, and qualified testing. Achieve plans to resubmit its NDA in Q4 2026, naming Adare as its primary partner, targeting approval in H1 2027. Let's check the other items: - ADC Therapeutics: "ADCT cuts jobs". Let's search for "ADC Therapeutics jobs" or "ADC Therapeutics restructuring" or "LOTIS-5" to see if there is any update to the ADC Therapeutics watch. The watch is: "Monitor ADC Therapeutics' planned sBLA submission in Q4 2026 following the pre-sBLA meeting with the FDA in August 2026 to see if safety concerns (13.2% fatal TEAEs in LOTIS-5) delay or alter the regulatory path." Let's search for "ADC Therapeutics" to see if they announced anything.

This is another magnificent update. Let's fetch the BioSpace article on ADC Therapeutics' layoffs and LOTIS-5 trial readout. This is highly relevant to our watch.

This is incredibly useful. Let's see what else we can check. We have: - **Tavneos (avacopan)**: CHMP recommended revoking marketing authorization on June 26, 2026. The FDA hearing submission deadline was extended to July 29, 2026 (it was June 29). - **Yartemlea (narsoplimab)**: CHMP adopted negative opinion on June 26, 2026. Omeros intends to request re-examination and seek review by an Ad Hoc Expert Group (AHEG). - **Zynlonta (loncastuximab tesirine-lpyl)**: ADC Therapeutics announced a 17% workforce reduction (about 30-32 roles) on June 24, 2026, to preserve cash (extending runway to 2028) and focus on its Zynlonta pre-sBLA meeting in August 2026. This follows the LOTIS-5 confirmatory trial readout where 27 patient deaths occurred in the treatment arm (vs 9 in control) and no overall survival benefit was demonstrated, crashing the stock 66% since June 4, 2026. They still plan to submit the sBLA in Q4 2026. - **Cytisinicline**: FDA issued a CRL to Achieve Life Sciences on June 22, 2026, due to third-party manufacturing deficiencies (at its prior third-party partner) and incomplete labeling, with no safety or efficacy concerns. Achieve has already transitioned to US-based Adare Pharma Solutions and plans to resubmit the NDA in Q4 2026, targeting approval in H1 2027. Wait, are there any updates on other watches? Let's check some of the other late July / mid-2026 watches: 1. "FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting scheduled for July 29, 2026, to discuss Capricor's BLA for deramiocel in DMD cardiomyopathy." Let's search for "Capricor deramiocel BLA" or "Capricor FDA" to see if there is any update on this. 2. "FDA advisory committee meeting scheduled for late July 2026 to discuss Replimune's resubmitted BLA for RP1 in advanced melanoma, ahead of the August 2, 2026 PDUFA target action date." Let's search for "Replimune RP1 FDA" or "Replimune advisory committee" to see if any updates have occurred. 3. "MoonLake's primary endpoint readout of the Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis (PsA), expected in mid-2026." Let's search for "MoonLake sonelokimab" or "IZAR-1" or "IZAR-1 trial results". 4. "GondolaBio's global Phase 2b/3 PATHWAY trial of PORT-77 in patients with EPP and XLP, targeted for Q3 2026." Let's search GondolaBio PORT-77. Let's do a search for these items.

This is a major update! Let's fetch the BioSpace article on Capricor. "Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy" Let's fetch this.

This is incredibly helpful! It gives a complete picture of what is going on at the FDA right now, and directly links to several of our findings and watches. Let's summarize the key points from this article: 1. **Capricor's deramiocel**: - The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee has scheduled an advisory committee meeting (AdCom) on **July 29, 2026** to discuss Capricor's BLA for deramiocel in DMD cardiomyopathy. - PDUFA Target Action Date is **August 22, 2026**. - This was a surprise to Capricor's CEO Linda Marbán, as they believed the HOPS-3 Phase 3 randomized double-blind placebo-controlled trial dataset was extremely clean (hitting primary and secondary endpoints). - This directly updates the existing watch: "FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy" (fire date is indeed July 29, 2026, and PDUFA is Aug 22, 2026). 2. **Replimune's RP1**: - The FDA has accepted Replimune's resubmitted BLA for RP1 in advanced melanoma, but has scheduled an advisory committee meeting for **late July 2026**, ahead of the **August 2, 2026** PDUFA target action date. - This matches our watch: "FDA advisory committee meeting and PDUFA date for Replimune's RP1 in advanced melanoma." 3. **FDA Post-Makary/Prasad Normalization**: - The article notes that the FDA's recent trend under acting FDA Commissioner Kyle Diamantas (or general agency shifts) is a return to scheduling advisory committee meetings (AdComs) to ensure careful review, especially in the Duchenne space (given prior issues with Sarepta's Elevidys) and oncology/vaccines. - This directly ties to our standing finding: `[[fda-regulatory-pivot-advisory-committees-capricor-replimune]]` (The Post-Makary FDA Pivot: Reversals, Resubmissions, and a Return to Advisory Committees). We should update this finding with these fresh developments (Capricor and Replimune's AdComs being officially scheduled/announced, and the context of acting FDA Commissioner Kyle Diamantas wanting more AdComs). Wait, let's search for "Kyle Diamantas FDA commissioner" or "acting FDA Commissioner Kyle Diamantas" to confirm the leadership transition at the FDA, as Marty Makary and Vinay Prasad left in May 2026. This is a crucial piece of federal health policy. Let's search!

This is extremely helpful for our policy understanding. Marty Makary resigned in mid-May 2026, and Kyle Diamantas, J.D. (who was previously Deputy Commissioner for Human Foods) was appointed Acting Commissioner. The shift toward scheduling more advisory committee meetings is a key policy change under Diamantas. Let's review the other watches. Are there any updates on: 1. "MoonLake's primary endpoint readout of the Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis (PsA), expected in mid-2026." Let's search for "MoonLake IZAR-1 sonelokimab". 2. "GondolaBio's global Phase 2b/3 PATHWAY trial of PORT-77 in patients with EPP and XLP, targeted for Q3 2026." Let's search for "GondolaBio PATHWAY PORT-77". 3. "MoonLake's planned Biologics License Application (BLA) submission to the FDA for sonelokimab (SLK) in moderate-to-severe hidradenitis suppurativa (HS), targeted for late September 2026" Let's check if there are any updates on this. 4. "NHS-Galleri trial cancer mortality data release" (ongoing watch) Let's search "NHS-Galleri trial mortality". Let's do a search.

This is fantastic! Let's fetch the GlobeNewswire press release from MoonLake: "MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026." This gives us a major clinical trial readout update! Let's fetch this.

This is an incredibly positive update for MoonLake! Let's analyze what we have: - **Trial**: Phase 3 VELA-1 and VELA-2 trials of sonelokimab (SLK), an IL-17A/F nanobody, in moderate-to-severe hidradenitis suppurativa (HS). Also the Phase 3 VELA-TEEN trial in adolescents. - **Results**: - At Week 52, 67.2% of adult patients treated with SLK achieved HiSCR75, 33.1% achieved HiSCR100, and 26.0% achieved IHS4-100 (inflammatory remission). This is superior to competing Phase 3 programs (e.g., competing IL-17A/F inhibitors showed ~10% fewer responding patients). - High quality of life improvements (HiSQOL score difference of -15.0 points, indicating change from "severe" to "mild" impairment; 75.0% and 69.4% achieved clinically meaningful DLQI improvement). - 46.5% of patients experienced a marked reduction in pain. - VELA-TEEN interim Week 24 results: ~68% achieved HiSCR75, ~86% achieved HiSCR50, and ~45% achieved HiSCR100. - **Regulatory Strategy**: BLA submission for sonelokimab in HS is expected at the end of September 2026, including data from adolescent patients, with a PDUFA date allocation expected in late November 2026. - This directly updates the existing watch: "MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa" (fire date is late September 2026, and subsequent PDUFA allocation is late November 2026). Wait, let's look for other watches. "GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP" Let's search for "GondolaBio PATHWAY PORT-77" to see if there is any update on this. Let's do a search.

This is absolutely major! GondolaBio announced positive Phase 2a GATEWAY trial results for PORT-77 in EPP (erythropoietic protoporphyria) on June 22, 2026. Let's fetch the BusinessWire release: "GondolaBio Announces Positive Phase 2a Results Demonstrating 79% Plasma Protoporphyrin IX Reduction and Disease-Modifying Potential of PORT-77 for Erythropoietic Protoporphyria" This is a brand-new clinical trial readout that directly impacts the EPP therapeutic landscape (which we track under slug `disc-medicine-bitopertin-epp-crl-path`). Let's fetch this.

Ah, the web_search budget is spent. That's perfectly fine because we have an extraordinary and detailed set of updates that cover multiple standing threads and provide fresh, high-quality, primary-source-backed findings. Let's double check the notes and threads we have. We have the following standing prior findings: 1. `hhs-clinical-trials-reform-operation-trialblazer` 2. `fda-regulatory-pivot-advisory-committees-capricor-replimune` 3. `belite-bio-tinlarebant-stargardt-disease-nda` 4. `cdc-blocked-covid-vaccine-study-published-jama` 5. `disc-medicine-bitopertin-epp-crl-path` Let's look at what we can update and what new notes we can write: 1. We should update `fda-regulatory-pivot-advisory-committees-capricor-replimune` with the official scheduling of the AdComs for Capricor's deramiocel (July 29, 2026) and Replimune's RP1 (late July 2026), and the broader context of acting FDA Commissioner Kyle Diamantas wanting more AdComs. 2. We should update `disc-medicine-bitopertin-epp-crl-path` with the positive Phase 2a GATEWAY data for GondolaBio's PORT-77, which showed a rapid 79% reduction in plasma PPIX (the most ever reported) and has set the stage for its Phase 2b/3 PATHWAY trial in Q3 2026. 3. We should write a new finding for "Amgen's Tavneos EU Revocation and US FDA Hearing Extension". - Slug: `amgen-tavneos-eu-revocation-fda-hearing-extension` - Subject: The CHMP's recommendation to revoke Tavneos's marketing authorization due to GCP breaches and "incorrect/misleading" data in the ADVOCATE trial, and the FDA extending Amgen's hearing submission deadline to July 29, 2026. 4. We should write a new finding for "Achieve Life Sciences Cytisinicline CRL and Transition to Adare". - Slug: `achieve-life-sciences-cytisinicline-crl-manufacturing-transition` - Subject: Achieve's CRL from the FDA on June 22, 2026 due to manufacturing deficiencies at a prior third-party partner, and their transition to Adare Pharma Solutions with plans to resubmit the NDA in Q4 2026. 5. We should write a new finding for "Omeros Yartemlea Negative CHMP Opinion and Re-examination Request". - Slug: `omeros-yartemlea-negative-chmp-opinion-reexamination` - Subject: Omeros's Yartemlea (narsoplimab) receiving a negative CHMP opinion on June 26, 2026, and Omeros's plans to request a re-examination and seek review by an Ad Hoc Expert Group (AHEG). 6. We should write a new finding for "ADC Therapeutics Restructuring and sBLA Strategy Post-LOTIS-5 Safety Concerns". - Slug: `adc-therapeutics-restructuring-zynlonta-lotis-5-safety` - Subject: ADC Therapeutics' 17% workforce reduction on June 24, 2026, following the LOTIS-5 trial's elevated mortality rate (27 deaths in treatment arm vs 9 in control) and no OS benefit, while still planning a pre-sBLA FDA meeting in August 2026 and sBLA submission in Q4 2026. 7. We should write a new finding for "MoonLake Sonelokimab 52-Week Phase 3 VELA Results in Hidradenitis Suppurativa". - Slug: `moonlake-sonelokimab-vela-phase-3-hidradenitis-suppurativa` - Subject: MoonLake's robust 52-week results from VELA-1 and VELA-2 trials showing 67.2% HiSCR75 and 26% inflammatory remission, setting up a BLA submission in late September 2026. Wait, let's look at the instruction: "For each distinct theme or story worth persisting, call write_note — ONE note per theme, never a combined write-up. A finding TELLS THE STORY THROUGH CONCRETE EVIDENCE — it does not just describe the vibe." "Carry 1-2 REPRESENTATIVE VERBATIM QUOTES, copied exactly, each kept with the link it came from (an HN comment permalink, the article URL, etc.), then say what it means." "No YAML frontmatter — the title is the first `# ` heading and the slug is the slug parameter you pass." "To link ANOTHER finding from a note body, write its slug as a wikilink — `[[its-slug]]`." Let's read the current standing notes to see what's in them so we can update them appropriately. I can call `read_notes` first. Let's do that!

Ah! The notes are extremely comprehensive. It looks like some notes were already written in a previous cycle (e.g. `amgen-tavneos-chmp-revocation-data-integrity`, `omeros-narsoplimab-chmp-negative-opinion-ta-tma`, `moonlake-sonelokimab-phase3-vela-hidradenitis-suppurativa`, `disc-medicine-bitopertin-epp-crl-path`, `fda-regulatory-pivot-advisory-committees-capricor-replimune`). Let's carefully check the slugs we have: 1. `amgen-tavneos-chmp-revocation-data-integrity` is already a note! Let's update it with the new information: the FDA's extension of Amgen's hearing submission deadline to July 29, 2026. 2. `omeros-narsoplimab-chmp-negative-opinion-ta-tma` is already a note! Let's update it with the negative CHMP opinion and Omeros's plan to request re-examination and seek review by an Ad Hoc Expert Group (AHEG). 3. `moonlake-sonelokimab-phase3-vela-hidradenitis-suppurativa` is already a note! Let's update it with the 52-week results of VELA-1 and VELA-2 and the VELA-TEEN interim results, plus the late-September BLA submission. 4. `disc-medicine-bitopertin-epp-crl-path` is already a note! Let's update it with GondolaBio's positive Phase 2a GATEWAY results and plans for the global Phase 2b/3 PATHWAY trial in Q3 2026. 5. `fda-regulatory-pivot-advisory-committees-capricor-replimune` is already a note! Let's update it with the official scheduling of Capricor's AdCom on July 29, 2026 and Replimune's AdCom in late July, plus Kyle Diamantas's policy direction of wanting more AdComs. 6. What about `achieve-life-sciences-cytisinicline-crl-manufacturing-transition`? This is a completely new finding from this week (June 22, 2026). Let's write a new note for it. 7. What about `adc-therapeutics-restructuring-zynlonta-lotis-5-safety`? Wait! There is `zynlonta-phase3-lotis5-dlbcl-safety-concerns` in our list of prior findings! Let's update that existing note (`zynlonta-phase3-lotis5-dlbcl-safety-concerns`) with the June 24, 2026 announcement of a 17% workforce reduction to save $10 million annually, and the upcoming pre-sBLA meeting in August 2026. This is extremely clean. I will update these existing notes and create the new note for Achieve Life Sciences' cytisinicline CRL. Let's do a quick write-up of each note. First, let's look at `amgen-tavneos-chmp-revocation-data-integrity` to see its current content so we can merge the new findings nicely. Wait, I don't have to read it in full if I can just write the new updated note, but let's make sure it contains the previous context plus the new updates. Let's draft the body of each note. ### Note 1: `amgen-tavneos-chmp-revocation-data-integrity` Let's update this note. The new developments: - On June 26, 2026, the European Medicines Agency's CHMP officially recommended revoking the marketing authorization for Tavneos (avacopan) in the EU, stating that the pivotal ADVOCATE study breached GCP principles, and that the data was "incorrect and misleading and could no longer be relied upon." - In the U.S., the FDA extended Amgen's deadline for submitting supporting materials for the formal hearing to **July 29, 2026** (it was previously June 29). Let's write this note. Let's make sure we quote the Fierce Pharma or BioWorld article. Quote from Fierce Pharma: > "The CHMP has now determined that the Advocate study was 'conducted in breach of good clinical practice (GCP) principles,' adding that the data provided for the assessment 'were found to be incorrect and misleading and could no longer be relied upon for demonstrating Tavneos’ effectiveness.'" And: > "The deadline for our hearing submission has been extended to July 29, and we remain engaged with the FDA as the regulatory process continues in the United States." Let's write the note.

Fantastic! Now let's update `omeros-narsoplimab-chmp-negative-opinion-ta-tma` (or the prior slug `omeros-narsoplimab-chmp-negative-opinion-ta-tma` as retrieved in `read_notes`). Let's check the slug in `read_notes`: yes, `omeros-narsoplimab-chmp-negative-opinion-ta-tma`. Let's update it. The new developments: - On June 26, 2026, the CHMP officially adopted a negative opinion on Omeros's MAA for narsoplimab (Yartemlea) in TA-TMA. - Omeros announced its intention to request a re-examination of the CHMP opinion and, as part of that procedure, to seek review by an Ad Hoc Expert Group (AHEG), which is an independent panel of external clinical experts. - Omeros plans to continue providing the drug to patients under its global compassionate use program, prioritizing children, while the regulatory review progresses. Let's write this note. Let's make sure we quote the BioSpace press release. Quote from BioSpace: > "Following an oral explanation meeting with the CHMP held this week, at which Omeros presented its position together with four international experts in hematopoietic cell transplantation, Omeros was informed that the CHMP has adopted a negative opinion on the MAA for narsoplimab in TA-TMA." And Gregory Demopulos: > "We are disappointed by the CHMP's opinion, particularly given the lethal nature of TA-TMA, the absence of an approved treatment for this condition in Europe, and the totality of the clinical trial and real-world data supporting narsoplimab's efficacy and safety." Let's write the note.

Excellent! Let's update `moonlake-sonelokimab-phase-3-vela-hidradenitis-suppurativa` (let's check the exact slug from `read_notes`: there is `moonlake-sonelokimab-phase-3-vela-hidradenitis-suppurativa` and `moonlake-sonelokimab-phase3-vela-hidradenitis-suppurativa` and `moonlake-sonelokimab-vela-hidradenitis-suppurativa`. The most detailed one is `moonlake-sonelokimab-phase-3-vela-hidradenitis-suppurativa` or `moonlake-sonelokimab-phase3-vela-hidradenitis-suppurativa`. Let's update `moonlake-sonelokimab-phase-3-vela-hidradenitis-suppurativa`). The new developments: - On June 21, 2026, MoonLake reported the final Week 52 (one-year) results from its Phase 3 VELA-1 and VELA-2 trials in moderate-to-severe hidradenitis suppurativa (HS). - Results showed that 67.2% of adult patients treated with sonelokimab (SLK) achieved HiSCR75 at Week 52, 33.1% achieved HiSCR100, and 26.0% achieved IHS4-100 (complete inflammatory remission). - Crossover patients who switched from placebo to SLK at Week 16 achieved similar high clinical responses (~60% HiSCR75 after 36 weeks of active treatment). - Interim Week 24 results from the Phase 3 VELA-TEEN trial in adolescent HS patients showed strong response, with ~68% achieving HiSCR75 and ~45% reaching HiSCR100, with no new safety signals. - MoonLake confirmed it is on track to submit its Biologics License Application (BLA) to the FDA for sonelokimab in HS in **late September 2026**, with subsequent PDUFA target action date allocation expected in late November 2026. Let's write this note. Let's make sure we quote the GlobeNewswire press release. Quote: > "Across both VELA-1 and VELA-2, 67.2% of patients treated with SLK achieved HiSCR75 and 33.1% achieved HiSCR100 at Week 52 (n=396)." And: > "Submission of the Biologics License Application (BLA) for SLK in HS, including data from adolescent patients, is expected at the end of September 2026, and will follow previous agency guidance on the label strategy." Let's write this note.

Awesome! Now let's update `disc-medicine-bitopertin-epp-crl-path`. The new developments: - On June 22, 2026, GondolaBio announced positive results from its Phase 2a GATEWAY trial of PORT-77, an oral, small-molecule ABCG2 inhibitor designed to treat erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). - Results showed that PORT-77 met its primary endpoint, demonstrating rapid, dose-dependent reductions in plasma protoporphyrin IX (PPIX). The high-dose cohort (300 mg BID) achieved a mean decrease of 79% in plasma PPIX, and the low-dose cohort (180 mg QD) achieved a mean decrease of 63%. - Reductions occurred within hours of treatment, representing the greatest PPIX reduction rates reported for any EPP or XLP intervention to date. - PORT-77 was well tolerated, with no serious adverse events or treatment discontinuations. - Based on these findings and recent alignment with the FDA at an End-of-Phase 2 meeting, GondolaBio plans to initiate its global Phase 2b/3 PATHWAY trial in Q3 2026. This trial is highly anticipated and intensifies competition in the EPP landscape, which also features Disc Medicine's bitopertin and its planned Phase 3 APOLLO trial. Let's write this note. Let's make sure we quote the BusinessWire press release. Quote: > "Trial met its primary endpoint of plasma PPIX reduction, reaching a mean decrease of 79% in the high dose cohort, and 63% in the low dose cohort" And: > "Based on these results and general alignment at the End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) this month, GondolaBio plans to initiate the global Phase 2b/3 PATHWAY trial evaluating the safety and efficacy of PORT-77 in patients with EPP and XLP in Q3 2026." Let's write this note.

Perfect! Now let's update `fda-regulatory-pivot-advisory-committees-capricor-replimune`. The new developments: - The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee has scheduled an advisory committee meeting (AdCom) on **July 29, 2026** to discuss Capricor's BLA for deramiocel in DMD cardiomyopathy. - The FDA has also accepted Replimune's resubmitted BLA for RP1 in advanced melanoma and scheduled an AdCom for **late July 2026**, ahead of its August 2, 2026 PDUFA date. - These scheduled AdComs represent a major policy shift toward a return to advisory committees under Acting FDA Commissioner Kyle Diamantas, J.D., who stepped in following Marty Makary's resignation in mid-May 2026. Diamantas has reportedly stated he wants more AdComs to ensure thorough public review of controversial or rare disease therapies, reversing the previous leadership's unilateral cancelations. Let's write this note. Let's make sure we quote the BioSpace article. Quote: > "Linda Marbán was 'surprised' when the FDA informed Capricor Therapeutics it would be holding an advisory committee meeting for its Duchenne muscular dystrophy cardiomyopathy cell therapy prior to its August target action date." And: > "We did hear that [acting FDA Commissioner] Kyle Diamantas . . . said he wanted more adcomms, and so we’re kind of wondering if this is sort of in response to that" Let's write this note.

Fantastic! Now let's write the new note for Achieve Life Sciences' cytisinicline CRL: `achieve-life-sciences-cytisinicline-crl-manufacturing-transition`. Let's write this note. Let's make sure we quote the AJMC article. Quote: > "The CRL relates to outstanding manufacturing observations from a current Good Manufacturing Practice (cGMP) inspection of a prior third-party manufacturing partner..." And: > "Achieve plans to resubmit its NDA in the fourth quarter of 2026, naming Adare as its primary manufacturing partner, with potential FDA approval targeted for the first half of 2027..." Let's write the note.

Excellent! Now let's update the existing note `zynlonta-phase3-lotis5-dlbcl-safety-concerns` with the June 24, 2026 restructuring and layoffs. Let's read the prior note's preview or check our facts: - The previous note was titled: "Zynlonta Confirmatory Phase 3 Trial Meets PFS Endpoint but Staggering 3-to-1 Death Imbalance Clouds FDA Path". - The new developments: - On June 24, 2026, ADC Therapeutics announced a strategic reorganization and a **17% global workforce reduction** (affecting approximately 30-32 roles) to save $10 million annually and preserve its cash runway into 2028. - This downsizing is a direct response to the recent safety setback in the Phase 3 LOTIS-5 trial of Zynlonta (loncastuximab tesirine-lpyl) plus rituximab in relapsed/refractory DLBCL, where 27 patient deaths occurred in the treatment arm (vs 9 in control) and no overall survival benefit was demonstrated, crashing the stock 66% in a month. - Despite the setback, CEO Ameet Mallik stated that the company remains focused on its upcoming regulatory milestones and plans to proceed with a pre-sBLA meeting with the FDA in **August 2026** and submit the sBLA for expanded approval in **Q4 2026**. Let's write this note. Let's make sure we quote the BioSpace article. Quote: > "After reporting more than two dozen deaths of trial participants taking blood cancer drug Zynlonta, Swiss biopharma ADC Therapeutics is laying off 17% of its team in hopes of saving $10 million per year." And Ameet Mallik: > "As we further assess the Phase 3 LOTIS-5 trial outcomes, including feedback from key medical experts, we continue to believe in the favorable overall benefit-risk profile and look forward to our pre-supplemental Biologics License Application (sBLA) meeting with the U.S. Food and Drug Administration in August..." Let's write this note.

This is incredible. We have updated multiple standing notes with the latest primary-source-backed findings. Let's double check if there are any other notes to write or update. We have: - `amgen-tavneos-chmp-revocation-data-integrity` (updated) - `omeros-narsoplimab-chmp-negative-opinion-ta-tma` (updated) - `moonlake-sonelokimab-phase-3-vela-hidradenitis-suppurativa` (updated) - `disc-medicine-bitopertin-epp-crl-path` (updated) - `fda-regulatory-pivot-advisory-committees-capricor-replimune` (updated) - `achieve-life-sciences-cytisinicline-crl-manufacturing-transition` (created new finding) - `zynlonta-phase3-lotis5-dlbcl-safety-concerns` (updated) Wait! Let's check if we have any other open threads or watches to resolve. Let's review the threads/watches: 1. `019f0620-0add-7ac7-9db1-1ce428418522` (EMA re-examination outcome on Omeros's narsoplimab in TA-TMA): - Trigger: "Fires when the EMA or Omeros announces the outcome of the re-examination and AHEG review." - Outcome: Omeros announced the negative CHMP opinion on June 26, 2026, and its intention to request a re-examination and seek review by an Ad Hoc Expert Group (AHEG). This means the re-examination process is *starting now* rather than completing. So we shouldn't resolve this watch yet, as the final outcome is still several months away. However, we can record an event for it with `resolves: false` to show that the initial negative opinion has fired the re-examination process. 2. `019f0620-007b-7dab-87b4-0363a2496ea1` (FDA advisory committee meeting and PDUFA date for Replimune's RP1 in advanced melanoma): - This watch is for the AdCom in late July and PDUFA on Aug 2, 2026. This has not happened yet, but we've updated its status. 3. `019f061f-f34a-7079-a276-d216329928b2` (FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy): - This watch is for the AdCom on July 29, 2026. This has not happened yet, but we've updated its status. 4. `019ef6aa-0088-716a-a75d-6adbc6f4984d` (GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP): - This watch is for the trial initiation in Q3 2026. We've updated its status in `disc-medicine-bitopertin-epp-crl-path`. 5. `019ef183-efef-70f6-9f55-cbbd11c943bb` (MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa): - This watch is for the BLA submission in late September 2026. We've updated its status. 6. `019e9f1e-b37e-771d-884b-b07383d792b7` (sBLA submission for Zynlonta plus rituximab in r/r DLBCL): - This watch is for the sBLA submission in Q4 2026. We've updated its status. 7. `019ec855-5381-7936-a3b6-a40d207e679d` (Amgen Tavneos FDA hearing submission and public docket close): - This watch had a fire date of June 29, 2026. The trigger was "Fires when Amgen submits its evidence and the public docket closes on June 29, 2026." - However, we found that the FDA has extended the deadline to **July 29, 2026**. - This is a major update to the watch! We should record an event on this watch to note the deadline extension and keep the watch open (`resolves: false`) with a new expectation. Wait, we can't edit the watch's fire_date directly, but we can record an event and record a new watch if needed, or just record an event with `resolves: false` and note the extension. Let's record the event on the Amgen Tavneos watch `019ec855-5381-7936-a3b6-a40d207e679d`. Let's do that!

Fantastic! Now let's record an event on the Omeros narsoplimab watch `019f0620-0add-7ac7-9db1-1ce428418522` to note that the CHMP adopted a negative opinion, triggering Omeros's request for re-examination and AHEG review. Let's do that!

Outstanding! Now let's register a new watch for the newly surfaced clinical/regulatory milestone: - Achieve Life Sciences' cytisinicline NDA resubmission, planned for Q4 2026. Let's call `record_watch`.

Perfect! Let's write to our long-term memory to keep track of these updates. Wait, let's look at our guideline: "Before modifying a file, read it first. Do not assume files or directories exist." Let's read the long-term memory file `/var/lib/hey-lefty/notes/765a8ac6-f588-4173-adba-058c75bb673f/019e92c9-9dac-7a47-a1f2-f8f4037c94f9/memory/MEMORY.md` if it exists. Wait, I can just use standard Unix shell tools or similar if I had them, but I don't see any shell tools declared. Oh, I don't have shell tools in my declarations, I only have `default_api` tools like `list_threads`, `read_notes`, `write_note`, `record_thread`, `resolve_thread`, `record_watch`, `record_event`, `web_search`, `web_fetch`, and `finish_cycle`. Wait, let me look at the declarations. Yes! I only have the `default_api` tools. I do not have standard os/file tools. That means I cannot read or write `/var/lib/hey-lefty/notes/.../memory/MEMORY.md` directly. That is totally fine, as my primary task is to run the research cycle, write notes using `write_note`, record watches, and call `finish_cycle`. Let's review if there is anything else. No, we have successfully: - Updated `amgen-tavneos-chmp-revocation-data-integrity` - Updated `omeros-narsoplimab-chmp-negative-opinion-ta-tma` - Updated `moonlake-sonelokimab-phase-3-vela-hidradenitis-suppurativa` - Updated `disc-medicine-bitopertin-epp-crl-path` - Updated `fda-regulatory-pivot-advisory-committees-capricor-replimune` - Created new finding `achieve-life-sciences-cytisinicline-crl-manufacturing-transition` - Updated `zynlonta-phase3-lotis5-dlbcl-safety-concerns` - Recorded event on the Amgen Tavneos watch (noting the deadline extension to July 29, 2026, and keeping it active) - Recorded event on the Omeros narsoplimab watch (noting the negative CHMP opinion and the upcoming re-examination, and keeping it active) - Registered a new watch for Achieve Life Sciences' cytisinicline NDA resubmission in Q4 2026. This is a remarkably successful research cycle with extremely fresh, high-impact clinical and regulatory findings. I will now call `finish_cycle` to complete this cycle.

I have successfully completed the research cycle for topic **019e92c9-9dac-7a47-a1f2-f8f4037c94f9**. ### Summary of Findings & Updates: 1. **Amgen's Tavneos (avacopan)**: Updated `[[amgen-tavneos-chmp-revocation-data-integrity]]` to record that on June 26, 2026, the EMA's CHMP recommended revoking its EU marketing authorization due to Good Clinical Practice (GCP) breaches in the pivotal ADVOCATE trial. In the U.S., the FDA extended Amgen's hearing submission deadline to **July 29, 2026** (recorded event on the active watch). 2. **Omeros's Yartemlea (narsoplimab)**: Updated `[[omeros-narsoplimab-chmp-negative-opinion-ta-tma]]` with the CHMP's negative opinion on June 26, 2026, and Omeros's plans to request a formal re-examination and seek review by an Ad Hoc Expert Group (AHEG) (recorded event on the active watch). 3. **FDA Policy & Advisory Committees**: Updated `[[fda-regulatory-pivot-advisory-committees-capricor-replimune]]` with the official scheduling of AdComs for Capricor's deramiocel (**July 29, 2026**) and Replimune's RP1 (**late July 2026**). This return to public panels is a key policy direction under Acting FDA Commissioner **Kyle Diamantas, J.D.**, who stepped in after Marty Makary's resignation. 4. **Achieve Life Sciences' Cytisinicline**: Created `[[achieve-life-sciences-cytisinicline-crl-manufacturing-transition]]` to detail the FDA's Complete Response Letter (CRL) on June 22, 2026, which was triggered entirely by manufacturing deficiencies at its prior third-party partner with no clinical safety or efficacy concerns. Achieve has already transitioned to Adare Pharma Solutions and plans to resubmit its NDA in **Q4 2026** (registered a new watch). 5. **GondolaBio's PORT-77**: Updated the EPP landscape note `[[disc-medicine-bitopertin-epp-crl-path]]` with GondolaBio's positive Phase 2a GATEWAY results showing an unprecedented **79% mean reduction** in plasma protoporphyrin IX (PPIX) and their plans to initiate the global Phase 2b/3 PATHWAY trial in **Q3 2026**. 6. **MoonLake's Sonelokimab**: Updated `[[moonlake-sonelokimab-phase-3-vela-hidradenitis-suppurativa]]` with the stellar final Week 52 Phase 3 VELA results (67.2% HiSCR75 and 26% inflammatory remission) and positive interim Week 24 VELA-TEEN results in adolescents, keeping them on track for a **late September 2026 BLA submission**. 7. **ADC Therapeutics' Zynlonta**: Updated `[[zynlonta-phase3-lotis5-dlbcl-safety-concerns]]` to reflect the company's June 24, 2026 announcement of a **17% global workforce reduction** to preserve cash post-LOTIS-5 safety concerns, while still proceeding toward an August FDA pre-sBLA meeting and Q4 2026 sBLA submission.